The stock's fall snapped a three-day winning streak.

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $402.49, demonstrating a -1.13% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.55%. On ...

Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

This was the stock's third consecutive day of gains.

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

12月19日，专注于罕见病治疗的药品开发公司Vertex ...

摩根大通：将Vertex Pharmaceuticals的目标价从503美元下调至500美元，但维持“增持”评级。(格隆汇) ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the thirty-one ratings firms that are covering the firm, ...

导读：12月9日消息，Bluebird、Vertex/CRISPR的基因疗法，与美国CMS（美国联邦医疗保险和医疗补助服务中心）正式达成“按结果付费”的协议，将于明年1月正式推出新的支付模式。01 昂贵的基因疗法自2012年第一款基因疗法在欧盟获批上 ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $426.00 to $430.00 in a ...

Investors need to pay close attention to Vertex Pharmaceuticals (VRTX) stock based on the movements in the options market lately. Vertex Pharmaceuticals' suzetrigine is an investigational pain ...

Truist analyst Joon Lee lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $460 from $550 and keeps a Buy ...